Doctors recruited from some of the world's poorest countries to work in UK hospitals say they're being exploited Paul Kenyon reports from 8pm BBCRadio 4 Full programme available BBCSounds from 20:40
Paul Kenyon investigates the UK's large-scale recruitment and exploitation of foreign doctors from countries with the greatest need to retain their medical personnel.Paul Kenyon investigates the ‘brain drain’ of doctors from developing countries to work in the UK.
The large scale recruitment of foreign doctors from nations with the greatest need to retain their medical personnel is increasing on a massive scale. What’s more, thousands of doctors are being targeted despite guidance which says recruitment from developing countries should not happen. It is though - because the UK trains too few doctors and nurses and needs these staff to plug the gaps.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Concert to be held in memory of dad-of-two who died from brain tumourA concert will be held at the Hard Rock Cafe in Glasgow in memory of a dad-of-two who died from a brain tumour.
Read more »
After a stroke in an infant's brain, the right side of the brain compensates for loss of language in the left sideA clinical study conducted by researchers at Georgetown University Medical Center has found that for children who had a major stroke to the left hemisphere of their brain within days of their birth, the infant's brain was 'plastic' enough for the right hemisphere to acquire the language abilities ordinarily handled by the left side, while also maintaining its own language abilities.
Read more »
Boy's rare condition means eating the wrong food could leave him brain damagedOliver Robertson has a rare and potentially serious inherited disorder which restricts his diet and makes eating out with family difficult
Read more »
Cecilia Vicuña’s Brain Forest Quipu is a monumental sculpture made of wood, rope and bonesThe Chilean artist specialises in materials washed up and overlooked - just as she herself has been until a flurry of commissions, including this latest at Turbine Hall
Read more »
Distinct translatome changes in specific neural populations precede electroencephalographic changes in prion-infected miceAuthor summary Prions are infectious agents composed of a misfolded protein. When isolated from a mammalian brain and transferred to the same host species, prions will cause the same neurodegenerative disease affecting the same brain regions and cell types. This concept of selective vulnerability is also a feature of more common types of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s. To better understand the mechanisms behind selective vulnerability, we studied disease responses of five cell types with different vulnerabilities in prion-infected mice at two different disease stages. Responses were measured as changes to mRNAs undergoing translation, referred to as the translatome. Before prion-infected mice demonstrated typical disease signs, electroencephalography (a method used clinically to characterize neurodegeneration in humans) revealed brain changes resembling those in human prion diseases, and surprisingly, the translatomes of all cells were drastically changed. Furthermore, before electroencephalography changes emerged, three cell types made unique responses while the most vulnerable cell type did not. These results suggests that mechanisms causing selective vulnerability will be difficult to dissect and that therapies will likely need to be provided before clinical signs emerge and individually engage multiple cell types and their distinct molecular pathways.
Read more »
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate - The Journal of Prevention of Alzheimer's DiseaseBackground Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog11) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL23). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.
Read more »